Learning objectives
The reader should be able to recognize systemic clues to kidney disease, classify glomerular, tubulointerstitial, vascular, obstructive, and metabolic injury patterns, distinguish diabetic kidney disease from non-diabetic kidney disease, identify urgent systemic renal syndromes, choose targeted investigations, and coordinate disease-specific treatment with specialty teams.
20.1 The kidney as a systemic-disease organ
Systemic disease may injure the kidney through immune complexes, autoantibodies, endothelial dysfunction, monoclonal proteins, altered hemodynamics, metabolic toxicity, direct infiltration, obstruction, or medication effects. A nephrologist should begin with the kidney phenotype—albuminuria, hematuria, AKI, electrolyte abnormality, hypertension, or obstruction—and then use extrarenal findings to narrow the differential.
20.2 High-yield systemic diseases
Diabetes commonly causes albuminuric CKD with diabetic retinopathy, gradual eGFR decline, and a bland sediment, but non-diabetic kidney disease should be considered when there is abrupt decline, active sediment, nephrotic syndrome without typical features, short diabetes duration, or absent retinopathy. SLE and AAV cause immune-mediated GN; monoclonal gammopathies produce cast nephropathy, amyloidosis, MIDD, and other lesions; systemic sclerosis causes renal crisis and chronic vascular disease; HIV may cause collapsing FSGS or immune-complex disease; sickle cell disease causes hyperfiltration, albuminuria, hematuria, papillary necrosis, and CKD; sarcoidosis causes granulomatous interstitial nephritis and hypercalcemia-related injury.
Amyloidosis and monoclonal gammopathy of renal significance require tissue typing whenever possible. Congo red positivity establishes amyloid but mass spectrometry or validated immunohistochemistry is needed to type the fibril and direct therapy. A small M-protein can still cause severe kidney disease.
20.3 Injury-pattern framework
| Kidney phenotype | Systemic disease examples | First diagnostic priorities |
|---|---|---|
| Albuminuric or nephrotic glomerular disease | Diabetes, SLE, amyloidosis, monoclonal gammopathy, HIV | ACR/PCR, sediment, serology, monoclonal studies, biopsy when indicated |
| Active nephritic or RPGN phenotype | AAV, lupus nephritis, anti-GBM, IgA vasculitis, infection | Urgent sediment, ANCA, anti-GBM, complements, cultures, biopsy |
| Tubulointerstitial phenotype | Sarcoidosis, Sjögren disease, drugs, HIV, sickle cell disease | Electrolytes, bicarbonate, calcium, urine concentration, imaging, biopsy selectively |
| Vascular or TMA phenotype | Systemic sclerosis, malignant hypertension, APS, cancer, complement disorders | BP, CBC/platelets, smear, LDH, haptoglobin, urine, ADAMTS13/complement studies as indicated |
| Obstructive or infiltrative phenotype | Malignancy, retroperitoneal fibrosis, myeloma, prostate disease | Ultrasound or CT, bladder assessment, urgent decompression if indicated |
20.4 Targeted diagnostic approach
History should cover diabetes duration and control, autoimmune symptoms, cancer and infection history, medications, NSAIDs, supplements, sickle complications, occupational exposures, family history, and pregnancy. Examination should assess blood pressure, volume, rashes, purpura, arthritis, sclerodactyly, Raynaud phenomenon, neuropathy, lymphadenopathy, hepatosplenomegaly, and signs of malignancy or infection.
Initial laboratory studies include creatinine/eGFR, electrolytes, bicarbonate, albumin, CBC, urinalysis with microscopy, ACR/PCR, glucose/HbA1c, and lipid profile. Add tests based on phenotype: ANA, anti-dsDNA, C3/C4, ANCA PR3/MPO, anti-GBM, hepatitis and HIV, SPEP/UPEP with immunofixation and free light chains, calcium/phosphate/PTH, hemolysis markers, blood cultures, and disease-specific markers. ACE level is neither sensitive nor specific for sarcoidosis and should not be used alone to diagnose renal sarcoidosis.
Renal ultrasound evaluates obstruction, kidney size, cysts, and asymmetry. Doppler or CT angiography is reserved for a clinically meaningful renovascular question. Kidney biopsy is selective and particularly valuable when the diagnosis will change immunosuppression, clone-directed therapy, or cancer treatment.
20.5 Disease-specific management principles
In diabetic kidney disease, optimize glycemia, blood pressure, renin–angiotensin blockade for albuminuric hypertension or CKD when indicated and tolerated, SGLT2 inhibitor therapy in eligible patients, and additional risk-based therapies such as finerenone when appropriate. ACEi/ARB therapy is not automatically required in a normotensive patient without albuminuria and should not be combined. Monitor creatinine and potassium.
Scleroderma renal crisis requires immediate ACE inhibition, careful blood-pressure management, and coordinated rheumatology care. High-dose glucocorticoids may increase risk and should not be reflexively used. Malignant hypertension, microangiopathic hemolysis, thrombocytopenia, and AKI require urgent assessment for TMA and alternative causes.
For monoclonal gammopathy-associated disease, rapid hematology–nephrology coordination is essential. Cast nephropathy is a hematologic emergency requiring rapid clone-directed therapy and supportive care. Hypercalcemia, dehydration, infection, and nephrotoxins should be corrected. Amyloid therapy depends on fibril type and systemic involvement.
SLE and AAV require disease-specific KDIGO-based treatment. Sarcoidosis and IgG4-related disease may require corticosteroids or steroid-sparing therapy after infection and malignancy have been considered. HIV kidney disease requires antiretroviral therapy and biopsy-guided treatment. Sickle cell kidney disease benefits from blood-pressure and albuminuria management, avoidance of dehydration and nephrotoxins, and hematology coordination.
20.6 Supportive CKD and emergency care
Treat hyperkalemia, acidosis, edema, anemia, mineral-bone disease, and cardiovascular risk. Manage albuminuria with indicated renin–angiotensin blockade and SGLT2 inhibitors when eligible. Avoid unnecessary NSAIDs, contrast exposure, and duplicate renin–angiotensin therapy. Urgent obstruction requires decompression; suspected TMA, pulmonary–renal syndrome, scleroderma renal crisis, severe hypercalcemia, and cast nephropathy require disease-specific emergency pathways.
Clinical pearls
- A bland sediment and retinopathy support diabetic kidney disease but do not prove it.
- A small M-protein can cause major renal injury.
- ACE inhibition is life-saving in scleroderma renal crisis, but high-dose steroids may worsen risk.
- ACEi/ARB therapy should be linked to albuminuric CKD and tolerance, not prescribed indiscriminately.
- ACE levels do not diagnose sarcoidosis.
- TMA is a pattern requiring a cause-directed evaluation.
- Kidney biopsy is selective and often changes therapy.
- Treat the systemic disease and the kidney phenotype concurrently.
| Kidney phenotype | Representative causes | Priority evaluation |
|---|---|---|
| Albuminuric/nephrotic | Diabetes, SLE, amyloid, MGRS, HIV | ACR/PCR, sediment, serology, monoclonal studies, biopsy when indicated |
| RPGN/active sediment | AAV, LN, anti-GBM, IgA vasculitis, infection | ANCA, anti-GBM, complements, cultures, urgent biopsy |
| Vascular/TMA | Systemic sclerosis, APS, cancer, malignant hypertension | BP, smear, platelets, LDH, haptoglobin, cause-directed testing |
| Obstructive/infiltrative | Malignancy, myeloma, retroperitoneal fibrosis | Ultrasound/CT and urgent decompression when indicated |
Summary
Systemic diseases injure the kidney through several mechanisms, and accurate diagnosis depends on integrating kidney phenotype with extrarenal findings. The most useful framework separates glomerular, tubulointerstitial, vascular/TMA, obstructive, infiltrative, and metabolic patterns. Disease-specific treatment ranges from ACE inhibition in scleroderma renal crisis to clone-directed therapy in monoclonal gammopathy, immunosuppression in lupus/AAV, antiretroviral therapy in HIV, and SGLT2-based kidney protection in eligible diabetic CKD.
Question 1
Which finding most strongly suggests non-diabetic kidney disease in a patient with diabetes?
A. Gradual albuminuria with retinopathy B. Active sediment with RBC casts and abrupt eGFR decline C. Long-standing hypertension D. Mild albuminuria
Answer: B. Active sediment and rapid decline warrant evaluation for another kidney disease.
Question 2
What is the key emergency treatment in scleroderma renal crisis?
A. Immediate ACE inhibition B. High-dose cyclophosphamide for all patients C. Stop all antihypertensives D. Plasma exchange for all cases
Answer: A. ACE inhibition is life-saving and should begin promptly.
Question 3
A patient with anemia, hypercalcemia, AKI, and proteinuria has a small monoclonal spike. What is the correct conclusion?
A. The spike is too small to matter. B. Monoclonal gammopathy-associated kidney disease remains possible and needs urgent evaluation. C. Diabetes is the most likely cause. D. Kidney biopsy is never useful.
Answer: B. Small clones can cause major renal injury.
Question 4
Which test is least reliable as a stand-alone diagnostic test for sarcoidosis?
A. Tissue biopsy with granulomas after excluding infection B. Hypercalcemia assessment C. ACE level alone D. Chest imaging
Answer: C. ACE lacks adequate sensitivity and specificity.
Question 5
Which phenotype should trigger urgent hemolysis and TMA evaluation?
A. Isolated stable albuminuria B. Severe hypertension, thrombocytopenia, anemia, high LDH, and AKI C. Mild nocturia D. Normal blood pressure and bland urine
Answer: B. This is a TMA-compatible presentation.
Question 6
Which general statement about kidney biopsy is correct?
A. It is required in every systemic disease. B. It is never needed when serology is positive. C. It is most useful when the result will change treatment or prognosis. D. It should be avoided in all CKD.
Answer: C. Biopsy is strategic and risk-adjusted.